Important! Severe allergic transfusion reactions to group B/AB plasma or platelets in group O recipients are linked to α-Gal sensitization due to high titers of group B cross-reactive anti–α-Gal IgE.
@alphagal_info@AlphaGal_RES
https://t.co/tmNfvkJZ86
BREAKING 🧵
A gut bacterium is showing up — or rather disappearing — across all three phases of COVID-19.
Severely ill patients have less of it.
Recovered patients get it back.
Long COVID patients don't.
Its name is Faecalibacterium prausnitzii. And what it does explains a lot. 👇
Just saw an animated commercial on a US TV network about Long Covid. It's by the Washington Department of Health. Most govts. haven't even mentioned anything about Long Covid and many of the public are so unaware of the symptoms. This is a good start. https://t.co/83naJ6cykS
COVID INQUIRY: MODULE 3 REPORT
“Fundamental flaws in the UK’s approach to IPC [infection prevention & control] guidance, for example in relation to the use of PPE, put patients and healthcare workers at risk.”
— Baroness Hallett, Chair of the Covid Inquiry
Read more here… ⬇️
Fascinating biomarker research in Long COVID (and other conditions such as Chronic Lyme Disease) looking at capillary damage.🩸
Really exciting to see this work being done - if validated, this would be an accessible, non-invasive test for patients to get done! 😷
Eagerly awaiting future updates from @ImmunoFever Lab at MIT! 🙏
Thank you to Dr. Erin Nance (on TikTok and IG!)
A paper highlighting how much harder it is to manage Long Covid(and chronic illness) when you are poor. Pacing is a privilege.
Middle/upper-class -> more remission, better recovery trajectories
Working-class/poor -> more relapses, prolonged chronicity
https://t.co/0D8vmicQfH
“Science shouldn’t stop where profits do”
This feels like a perennial challenge, at least here in the US. Promising treatments abound, but no money to be made by big pharma. How do we combat this?
A 100-year-old antiparasitic drug derived from white pine needles — Suramin — is freely distributed by the WHO to treat African sleeping sickness… but remains CDC-restricted and unapproved for any other use in the US.
In 2017, Dr. Robert Naviaux (UC San Diego) gave one low dose to five boys with autism. Within hours to days: improved speech (one nonverbal child spoke his first full sentence), better eye contact, social engagement, and awareness — effects described in a peer-reviewed study as a temporary “metabolic reset.”
The catch? Suramin is off-patent, unprofitable, and the small trial nearly bankrupted the researcher. Larger studies have stalled for lack of funding.
It’s not a proven cure — experts stress we need big, rigorous trials — but the published results raise a fascinating question the establishment rarely asks: could some features of autism involve a treatable “cell danger response” rather than purely irreversible genetics?
Read the 2017 paper yourself (Annals of Clinical and Translational Neurology) and decide what’s worth investigating next.
Science shouldn’t stop where profits do.
Today I'm supporting a patient who went into hospital last week for innocuous treatment, caught something that is now pneumonia there, and is now readmitted with it, and is probably going to die.
WHY DO HOSPITALS NOT HAVE MITIGATION AGAINST AIRBORNE DISEASE TRANSMISSION.
For a long time, catching frequent viruses was considered both inevitable and harmless. But it turns out that common, seemingly-mild viruses have disturbing long-term health impacts. 1/
Jess Michaels, a survivor of 27 years, just spoke with unshakable courage before the world—for herself, for Virginia Giuffre, and for every survivor silenced for too long.
Her voice broke through decades of denial.
The survivors will be silent no longer.
The world must finally listen.
Thank you for your bravery and courage Jess 🫶🏻
#DemsUnited